Takeda's COVID-19 treatment
GPTKB entity
Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:collaboration |
gptkb:National_Institutes_of_Health_(NIH)
|
| gptkbp:developed_by |
gptkb:Takeda_Pharmaceutical_Company
|
| https://www.w3.org/2000/01/rdf-schema#label |
Takeda's COVID-19 treatment
|
| gptkbp:indication |
treatment of COVID-19 in hospitalized patients
|
| gptkbp:mechanism_of_action |
neutralizes SARS-Co V-2 virus
|
| gptkbp:regulatory_compliance |
under review
|
| gptkbp:route_of_administration |
intravenous
|
| gptkbp:targets |
gptkb:COVID-19
|
| gptkbp:type |
gptkb:monoclonal_antibody
|
| gptkbp:bfsParent |
gptkb:Lonza_Group
|
| gptkbp:bfsLayer |
6
|